Full text is available at the source.
The association between proton pump inhibitors use and clinical outcome of patients receiving immune checkpoint inhibitors therapy
Proton pump inhibitor use linked to outcomes in patients treated with immune checkpoint inhibitors
AI simplified
Abstract
Analysis of seven studies revealed no significant association between proton pump inhibitor (PPI) use and overall survival (OS) or progression-free survival (PFS) in patients undergoing immune checkpoint inhibitor (ICI) therapy.
- PPI use did not show a significant impact on overall survival (HR: 1.05, 95% CI: 0.79-1.40, P = 0.73).
- No significant difference was found in progression-free survival for PPI users compared to non-users (HR: 0.90, 95% CI: 0.66-1.23, P = 0.51).
- Subgroup analyses indicated that PPI use is associated with superior PFS in melanoma patients (HR: 0.50, 95% CI: 0.28-0.91, P = 0.02).
- In contrast, PPI use was linked to inferior PFS in non-small cell lung cancer (NSCLC) patients (HR: 1.17, 95% CI: 1.05-1.31, P = 0.006).
- The findings suggest that PPI therapy may benefit melanoma patients while potentially harming NSCLC patients undergoing ICI treatment.
AI simplified